224 related articles for article (PubMed ID: 20460521)
1. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
Blanco E; Bey EA; Khemtong C; Yang SG; Setti-Guthi J; Chen H; Kessinger CW; Carnevale KA; Bornmann WG; Boothman DA; Gao J
Cancer Res; 2010 May; 70(10):3896-904. PubMed ID: 20460521
[TBL] [Abstract][Full Text] [Related]
2. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
3. β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Zhang L; Chen Z; Yang K; Liu C; Gao J; Qian F
Mol Pharm; 2015 Nov; 12(11):3999-4010. PubMed ID: 26415823
[TBL] [Abstract][Full Text] [Related]
4. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
6. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
7. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
[TBL] [Abstract][Full Text] [Related]
8. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock.
Song CW; Chae JJ; Choi EK; Hwang TS; Kim C; Lim BU; Park HJ
Int J Hyperthermia; 2008 Mar; 24(2):161-9. PubMed ID: 18283592
[TBL] [Abstract][Full Text] [Related]
11. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.
Ma X; Huang X; Huang G; Li L; Wang Y; Luo X; Boothman DA; Gao J
Adv Healthc Mater; 2014 Aug; 3(8):1210-6. PubMed ID: 24532286
[TBL] [Abstract][Full Text] [Related]
12. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
[TBL] [Abstract][Full Text] [Related]
13. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
14. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
15. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Li Y; Feng M; Guo T; Wang Z; Zhao Y
Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
[TBL] [Abstract][Full Text] [Related]
16. Drug-interactive mPEG-
Gong F; Wang R; Zhu Z; Duan J; Teng X; Cui ZK
Drug Deliv; 2020 Dec; 27(1):238-247. PubMed ID: 32003299
[TBL] [Abstract][Full Text] [Related]
17. Preparation and antitumor evaluation of self-assembling oleanolic acid-loaded Pluronic P105/d-α-tocopheryl polyethylene glycol succinate mixed micelles for non-small-cell lung cancer treatment.
Wu H; Zhong Q; Zhong R; Huang H; Xia Z; Ke Z; Zhang Z; Song J; Jia X
Int J Nanomedicine; 2016; 11():6337-6352. PubMed ID: 27932881
[TBL] [Abstract][Full Text] [Related]
18. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
Jeong SY; Park SJ; Yoon SM; Jung J; Woo HN; Yi SL; Song SY; Park HJ; Kim C; Lee JS; Lee JS; Choi EK
J Control Release; 2009 Nov; 139(3):239-45. PubMed ID: 19619590
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
Dong Y; Chin SF; Blanco E; Bey EA; Kabbani W; Xie XJ; Bornmann WG; Boothman DA; Gao J
Clin Cancer Res; 2009 Jan; 15(1):131-9. PubMed ID: 19118040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
